Business Wire

Pradaxa ® (dabigatran etexilate) dual therapy showed lower rates of major bleeding versus triple therapy with warfarin in atrial fibrillation patients undergoing stent placement

INGELHEIM, Germany-- (BUSINESS WIRE)--The RE-DUAL PCI™ trial explored anticoagulation with Pradaxa ® (dabigatran etexilate) dual therapy without aspirin in non-valvular atrial fibrillation (AF) ...
FiercePharma

FDA Approves Pradaxa® (dabigatran etexilate mesylate) for Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism

FDA Approves Pradaxa® (dabigatran etexilate mesylate) for Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism Three pivotal trials showed PRADAXA as ...
FiercePharma

New Sub-Analyses Report Pradaxa® (dabigatran etexilate mesylate) May Be Associated With Better Patient Outcomes After a Major Bleeding Event Compared to Warfarin

New Sub-Analyses Report Pradaxa® (dabigatran etexilate mesylate) May Be Associated With Better Patient Outcomes After a Major Bleeding Event Compared to Warfarin RIDGEFIELD, Conn., Dec. 8, 2012 -- ...
Business Insider

Uninterrupted Pradaxa® (dabigatran etexilate mesylate) Showed Less Major Bleeding than Warfarin in Atrial Fibrillation Patients Undergoing Catheter Ablation

RIDGEFIELD, Conn., March 19, 2017 /PRNewswire/ -- Important new data from the RE-CIRCUIT® study show a better safety profile for Pradaxa® (dabigatran etexilate mesylate) compared to warfarin in atrial ...
Insurancenewsnet.com

Pradaxa® (dabigatran etexilate mesylate) Capsules Now on Formulary at Nation’s Top Heart Hospitals

RIDGEFIELD, Conn., July 21, 2011 /PRNewswire/ --Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that Pradaxa® (dabigatran etexilate mesylate) capsules has been added to hospital ...
TCTMD

New Pradaxa® (dabigatran etexilate mesylate) Data to be Presented at American College of Cardiology Scientific Session (ACC.14)

Presentations to include research around antidote for dabigatran, a post-hoc analysis of data from the RE-LY® trial and data from the GLORIA™-AF registry RIDGEFIELD, Conn. -- Boehringer Ingelheim ...
TCTMD

Efficacy and Safety Profile of Pradaxa® (dabigatran etexilate) Repeatedly Confirmed

Ingelheim, Germany – Boehringer Ingelheim wants to set the record straight following misleading statements that the British Medical Journal (BMJ) published today regarding Pradaxa® (dabigatran ...
Forbes

FDA Undertakes Safety Review of Dabigatran (Pradaxa)

The FDA announced today that it was initiating a safety review of dabigatran (Pradaxa, Boehringer Ingelheim). The review was prompted by reports of serious bleeding events in people taking the drug.
elEconomista

Pradaxa® (dabigatran etexilate) - first neworal anticoagulant in nearly 60 years receives final NICE recommendation for stroke prevention in atrial fibrillation in the UK1

On 15 March, the National Institute for Health and Clinical Excellence (NICE) has issued final guidance recommending the novel oral anticoagulant, Pradaxa ® (dabigatran etexilate) 2 as a ...
elEconomista

Pradaxa® (dabigatran etexilate) now approvedin over 100 countries for stroke prevention in atrial fibrillation

For media outside of the US, the UK & Canada only Over 100 countries have now approved Boehringer Ingelheim’s Pradaxa® for the prevention of stroke and systemic embolism for adult patients with the ...
EurekAlert!

2 new papers on dabigatran etexilate (Pradaxa) and intracranial hemorrhage

Dabigatran is an oral anticoagulant (blood thinner) approved by the US FDA in 2010 to lower the risk of stroke and prevent systemic embolism in persons with nonvalvular atrial fibrillation. Unlike ...